Latisse® (bimatoprost ophthalmic solution) 0.03% is indicated for the treatment of hypotrichosis of eyelashes, enhancing their growth in terms of length, thickness, and darkness. Safety precautions must be followed, including contraindications for hypersensitivity, monitoring for increased intraocular pressure, and potential side effects like iris pigmentation. Proper application using sterile applicators is essential to avoid contamination and unwanted hair growth in unintended areas.

1. The Science of LATISSE®
(bimatoprost ophthalmic solution) 0.03%

2. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Indication: LATISSE®
(bimatoprost ophthalmic solution) 0.03% is
indicated to treat hypotrichosis of the eyelashes by increasing their
growth, including length, thickness, and darkness.
Important Safety Information:
Contraindications: LATISSE®
is contraindicated in patients with
hypersensitivity to bimatoprost or any other ingredient in this product.

3. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Important Safety Information (cont’d)
Warnings and Precautions: In patients using LUMIGAN®
(bimatoprost
ophthalmic solution) 0.03% or other prostaglandin analogs for the
treatment of elevated intraocular pressure (IOP), the concomitant use
of LATISSE®
may interfere with the desired reduction in IOP. Patients
using prostaglandin analogs including LUMIGAN®
for IOP reduction
should only use LATISSE®
after consulting with their physician and
should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when the same formulation of
bimatoprost ophthalmic solution (LUMIGAN®
) was instilled directly onto
the eye. Although iridal pigmentation was not reported in clinical
studies with LATISSE®
, patients should be advised about the potential
for increased brown iris pigmentation which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening)
to periorbital pigmented tissues and eyelashes.

4. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Important Safety Information (cont’d)
Warnings and Precautions (cont’d): There is the potential for hair
growth to occur in areas where LATISSE®
solution comes in repeated
contact with skin surfaces.
LATISSE®
solution should be used with caution in patients with active
intraocular inflammation (eg, uveitis) because the inflammation may be
exacerbated.
LATISSE®
contains benzalkonium chloride, which may be absorbed by
soft contact lenses. Contact lenses should be removed prior to
application of solution and may be reinserted 15 minutes following its
administration.

5. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Important Safety Information (cont’d)
Adverse Reactions: The most frequently reported adverse events
were eye pruritus, conjunctival hyperemia, skin hyperpigmentation,
ocular irritation, dry eye symptoms, and erythema of the eyelid. These
events occurred in less than 4% of patients.
Dosage and Administration: Apply nightly directly to the skin of the
upper eyelid margin at the base of the eyelashes using the
accompanying applicators. Blot any excess solution beyond the eyelid
margin. Dispose of the applicator after one use. Repeat for the
opposite eyelid margin using a new sterile applicator. Do not apply to
the lower eyelash line.

6. Other Safety Information
Macular edema, including cystoid macular edema, has been reported
during treatment with bimatoprost ophthalmic solution (LUMIGAN®
) for
elevated intraocular pressure (IOP). LATISSE®
should be used with
caution in aphakic patients, in pseudophakic patients with a torn
posterior lens capsule, or in patients with known risk factors for
macular edema.
There have been reports of bacterial keratitis associated with the use
of multiple-dose containers of topical ophthalmic products.
Patients should also be informed of the possibility of disparity between
eyes in length, thickness, pigmentation, number of eyelashes or vellus
hairs, and/or direction of eyelash growth.
For more information on LATISSE®
, please refer to
full prescribing information.

7. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Is a Structural Prostaglandin Analog1
 Precise mechanism of action is
unknown
 LATISSE®
solution likely
penetrates the hair follicle via
the dermis
– The physicochemical
properties of LATISSE®
solution favor its effective skin
absorption to the dermis
where hair follicles reside
 LATISSE®
is believed to exert
its effects by stimulating the
prostamide receptor2,3
1. LATISSE®
[package insert]. Irvine, CA: Allergan, Inc.; 2008; 2. Woodward DF et al. Pharm Ther. 2008;120:71-80;
3. Woodward DF et al. Br J Pharmacol. 2008;153:410-419.
Molecular Structure of LATISSE®
(bimatoprost ophthalmic solution) 0.03%

8. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Increases Overall Eyelash Prominence
Precise mechanism of action is unknown1
1. LATISSE®
[package insert]. Irvine, CA: Allergan, Inc.; 2008; 2. Johnstone MA, Albert DM. Surv Ophthalmol. 2002;47(suppl 1):S185-S202;
3. Elder MJ. Ophthal Plast Reconstr Surg. 1997;13:21-25; 4. Na JI et al. Br J Derm. 2006;155:1170-1176; 5. Data on file. Allergan, Inc.
Stimulates transition
from telogen to
anagen5
Prolongs
anagen1
Normal Eyelash Cycle2-4
Effect of LATISSE®
 Percent of
eyelashes in
anagen1
Anagen
≈ 1-2 months
Catagen
≈ 15 days
Telogen
≈ 4-9 months
Exogen

9. A Multicenter, Double-Masked, Randomized,
Parallel Study Assessing the Safety and Efficacy
of Once-Daily Application of LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Compared With Vehicle in Increasing Overall
Eyelash Prominence
INVESTIGATORS
Alastair Carruthers, MA, BM, BCh Richard G. Glogau, MD
Jean Carruthers, MD Derek H. Jones, MD
Joel L. Cohen, MD Gary P. Lask, MD
Sue Ellen Cox, MD Stacy Smith, MD
Doris J. Day, MD Wm. Philip Werschler, MD
Lisa Donofrio, MD David Wirta, MD
Steven Fagien, MD, FACS Jessica Wu, MD
Dee Anna Glaser, MD Steven Yoelin, MD

10. Study Design to Measure Efficacy and Safety
 Randomized, multicenter, double-masked, vehicle-controlled trial
 Daily treatment for 4 months with 1-month posttreatment follow-up
 Primary efficacy measure
– Global eyelash assessment (GEA) scale
 Secondary efficacy measure
– Digital image analysis
 Safety measures
– Adverse events (AEs)
– Ocular—biomicroscopy, intraocular pressure (IOP), ophthalmoscopy
(dilated), and visual acuity
– Nonocular—pulse rate, blood pressure (systolic/diastolic)
Please see Important Safety Information on slides 2-6.

11. Primary Efficacy Measure Was a Validated
GEA Scale*
 To determine GEA score (a measure of eyelash prominence), raters
evaluated length, fullness, and color of both sets of upper eyelashes
 Responders were defined as persons with at least a 1-grade
improvement from baseline
Grade 1 – Minimal
Inclusion Criteria
Grade 2 – Moderate
Inclusion Criteria
Grade 3 – Marked Grade 4 – Very Marked
*Scale demonstrated reliability and reproducibility in a study of 68 subjects.
Data on file. Allergan, Inc.

12. Secondary Efficacy Measure Was
Digital Image Analysis
 Change from baseline to
week 16 in:
– Length measured in pixels within
the area of interest (AOI)
– Thickness measured in pixels
within AOI
– Darkness measured as intensity
 Standardized technology and
methodology
– Equipment and setting
– Alignment, position and lighting
– Image acquisition, calibration
Data on file. Allergan, Inc.
Please see Important Safety Information
on slides 2-6.

13. Subjects Instructed on Proper Application of
Study Medication
 Apply one drop of bimatoprost solution to the single-use-per-eye applicator
 Brush applicator along upper eyelash margin
 Repeat for the opposite eyelid margin using a new sterile applicator
 Dab or blot any excess medication
 Apply to a clean face at night after all makeup is removed
 Do not insert contact lenses until ≥15 minutes after application
 Do not apply to the lower eyelash line
 Additional applications of bimatoprost solution will not increase the growth of eyelashes
Data on file. Allergan, Inc.

14. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Applicators
 Proper use of LATISSE®
requires the accompanying FDA-approved sterile applicators1
 The FDA-approved sterile applicators are designed to help patients properly apply the product
– Volume of bimatoprost when applied to the eyelid margin with the applicator is ≈ 5% of the volume used as
an eyedrop2
 Do not apply LATISSE®
in the eye or to the lower lid1
 DO NOT APPLY in your eye or to the lower lid because excess hair growth outside the treatment area
may occur. ONLY use the sterile applicators supplied with LATISSE®
to apply the product1
 Do not allow the tip of the bottle or applicator to contact surrounding structures, fingers, or any other
unintended surface in order to avoid contamination by common bacteria known to cause infections.1
There
have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical
ophthalmic products
 LATISSE®
contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses
should be removed prior to application of LATISSE®
and may be reinserted 15 minutes following its
administration1
 It is possible for hair growth to occur in other areas of your skin that LATISSE®
frequently touches. Any
excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent
material to reduce the chance of this from happening. It is also possible for a difference in eyelash length,
thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash1
1. . LATISSE®
[package insert]. Irvine, CA: Allergan, Inc 2. Data on file. Allergan, Inc.
Please see Important Safety Information on slides 2-6.

15. Direct Application to the Eyelid Margin
Decreases Dose Volume
Dermal ApplicationEyedrop
Eyedrop Dermal Application
 Volume of bimatoprost applied to the upper eyelid margin with the
applicator is ~5% of the volume used as an eyedrop
Data on file. Allergan, Inc.

16. Subject Disposition of the Pivotal Trial
LATISSE®
(bimatoprost
ophthalmic solution) 0.03%
(n=137)
Completed
(n=131)
Completed
(n=126)
Early Terminations
AE (n=4)
Lack of efficacy (n=0)
Lost to follow-up (n=3)
Protocol violation (n=2)
Personal reasons (n=4)
Other (n=2)
Early Terminations
AE (n=4)
Lack of efficacy (n=0)
Lost to follow-up (n=0)
Protocol violation (n=0)
Personal reasons (n=1)
Other (n=1)
Vehicle
(n=141)
Enrolled/Randomized
(n=278)
Screened
(n=409)

17. Demographic Data:
Well Matched Across Age Group
Characteristics
LATISSE®
(bimatoprost
ophthalmic solution) 0.03%
(n=137)
Vehicle
(n=141)
Age in years (mean) 49.9 49.7
<45 (%) 44 (32.1) 43 (30.5)
45-65 (%) 82 (59.9) 88 (62.4)
>65 (%) 11 (8.0) 10 (7.1)
Min, Max 22, 77 22, 78
Sex
Female (%) 134 (97.8) 136 (96.5)
Male (%) 3 (2.2) 5 (3.5)
Race
Caucasian (%)* 109 (79.6) 116 (82.3)
Black (%) 0 1 (0.7)
Asian (%) 18 (13.1) 16 (11.3)
Hispanic (%) 6 (4.4) 5 (3.5)
Other (%) 4 (2.9) 3 (2.1)
*Higher percentage of lighter-skinned subjects likely due to technicalities of protocol-inclusion criteria (imaging criteria and baseline GEA score).
Data on file. Allergan, Inc.

18. LATISSE®
(bimatoprost ophthalmic solution) 0.03% Significantly
Increases Percentage of Subjects With 1-Grade Improvement
5.1%
14.6%
50.4%
*
69.3%
*
78.1%
*
78.6%
*
21.4%
18.4%19.9%
14.9%
7.8%
2.1%
0
10
20
30
40
50
60
70
80
90
1 4 8 12 16 20
Differences noted as early as week 1.
Last observation carried forward performed on weeks 1 to 16.
*P<.0001.
Percentage change reported above each data point.
GEA score 2 (moderate) at baseline
GEA score 3 (marked) at week 16
Week
SubjectsWithatLeasta1-Grade
ImprovementinGEAFromBaseline(%)
LATISSE®
(N=137)
Vehicle (N=141)
LATISSE®
Treated Subject
Individual results may vary. If discontinued, lashes will
gradually return to their previous appearance.
Patients should also be informed of the possibility of
disparity between eyes in length, thickness,
pigmentation, number of eyelashes or vellus hairs,
and/or direction of eyelash growth.
Please see Important Safety Information on slides 2-6.

19. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Significantly Improves Eyelash Length
*P=.001; †P<.0001.
Error bars = 2 standard error (SE).
Percentage change reported above each data point.
MeanChangeFromBaseline(mm)
Week
1 4 8 12 16 20
†
†
†
†
*
-0.20
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
1.2%
1.4%
2.3%
1.2%
1.4%
1.4%0.3%
25.9%
24.6%
20.6%
11.5%
4.2%
LATISSE®
(N=137)
Vehicle (N=141)
LATISSE®
treated subject representing
mean change in length at week 16
Baseline
Individual results may vary. If discontinued, lashes will gradually
return to their previous appearance.
Patients should also be informed of the possibility of disparity
between eyes in length, thickness, pigmentation, number of
eyelashes or vellus hairs, and/or direction of eyelash growth.

20. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Significantly Improves Eyelash Fullness/Thickness
*P<.0001.
Error bars = 2 SE.
Percentage change reported above each data point.
Week
MeanChangeFromBaseline(mm2
)
*
*
*
*
1 4 8 12 16 20
-0.10
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
9.9%
18.8%
11.7%10.2%10.1%
9.4%
5.1%
100.2%
106.0%
82.2%
34.6%
15.8%
LATISSE®
(N=136)
Vehicle (N=140)
LATISSE®
treated subject representing mean
change in fullness/thickness at week 16
Baseline
Individual results may vary. If discontinued, lashes will gradually
return to their previous appearance.
Patients should also be informed of the possibility of disparity
between eyes in length, thickness, pigmentation, number of
eyelashes or vellus hairs, and/or direction of eyelash growth.

21. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Significantly Improves Eyelash Darkness
*P<.05; †P<.0001.
Error bars = 2 SE.
Percentage change reported above each data point.
LATISSE®
treated subject representing
mean change in darkness at week 16
LATISSE®
(N=137)
Vehicle (N=141)
MeanChangeFromBaseline(units)
Week
*
†
††
†
ImprovementImprovement
-25
-20
-15
-10
-5
0
5
1 4 8 12 16 20
2.5% 3.0%
3.6%
1.9%2.4%
4.9%
0.9%
18.0%18.2%
15.1%
8.1%
4.3%
Baseline
Individual results may vary. If discontinued, lashes will gradually
return to their previous appearance.
Patients should also be informed of the possibility of disparity
between eyes in length, thickness, pigmentation, number of
eyelashes or vellus hairs, and/or direction of eyelash growth.

22. Incidence of AEs
Number of Subjects (%)
Most Frequently Reported
Adverse Events
LATISSE®
(n=137)
Vehicle
(n=141)
Eye pruritus 5 (3.6) 1 (0.7)
Conjunctival hyperemia* 5 (3.6)†
0 (0.0)
Skin hyperpigmentation 4 (2.9) 1 (0.7)
Eye irritation 3 (2.2) 2 (1.4)
Dry eye 3 (2.2) 1 (0.7)
Erythema of eyelid 3 (2.2) 1 (0.7)
*P<.05 vs vehicle; †
All cases of conjunctival hyperemia were fully resolved by the end of the study.
 Fewer than 4% of patients experienced treatment-related adverse events
Please see Important Safety Information on slides 2-6.

23. Iris Pigmentation
Increased iris pigmentation has occurred when the same
formulation of bimatoprost ophthalmic solution
(LUMIGAN®
) was instilled directly into the eye. Although
iridal pigmentation was not reported in clinical studies
with LATISSE®
(bimatoprost ophthalmic solution) 0.03%,
patients should be advised about the potential for
increased brown iris pigmentation which is likely to be
permanent1
No patients (0%) experienced iris pigmentation changes
(dermal application)
Lack of iris pigmentation change in the LATISSE®
trials
likely due to upper eyelid margin application2
1. LATISSE®
[package insert]. Irvine, CA: Allergan, Inc.; 2008; 2. Data on file. Allergan, Inc.

24. Effects on Ocular Safety
The reduction in IOP was not cause for clinical concern
– Mean IOP:
Baseline: 14.5 mm Hg both groups
Week 16: 13.7 mm Hg vehicle, 13.3 mm Hg bimatoprost
– Small, statistically significant between-group differences during
the study
All less than 1 mm Hg and not clinically relevant
– Average of subjects’ range of IOPs (maximum to minimum IOP)
during study (baseline to week 16) was 3.7 mm Hg for vehicle
and 3.9 mm Hg for LATISSE®
(bimatoprost ophthalmic solution)
0.03%

25. Pivotal Trial Summary: LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Significantly Improves Eyelash Length, Thickness, and Darkness
 LATISSE®
solution significantly improved eyelash prominence, length,
thickness, and darkness of eyelashes compared with vehicle
– The majority of subjects began to experience significant results by week 8
with full results in 12 to 16 weeks
 LATISSE®
solution was well tolerated when applied to the upper eyelid
margins of healthy adults daily for 4 months
Please see Important Safety Information on slides 2-6.

26. Perspectives on the Role of LATISSE®
(bimatoprost ophthalmic solution) 0.03%
as a Potential Catalyst for Your Practice
A Market Category in Medical Aesthetics

27. LATISSE®
(bimatoprost ophthalmic solution) 0.03%:
Could Be a Catalyst for Medical Aesthetics
1. 2009 – MWB Monthly DTC Tracker = Among MD Rx considerers, those considering facial injectables in the next 2 years = 54%; 2. Data on file. BCG/Harris
Consumer Quantitative Conjoint Research; Allergan, Inc., 2008; 3. Data on file. Kaiser Associates BEG MD Survey; Allergan, Inc., 2008; 4. Consumer A&U
06/09, n=192; 5. MD A&U 06/09, n=203.
More potential
patients.
More potential
procedures.
LATISSE®
has the potential to TRIPLE the aesthetic market
Please see Important Safety Information on slides 2-6.

28. 1. Data on file. Allergan, Inc. 2008. BCG Harris Consumer Quantitative Conjoint Research; 2. Data on file. LATISSE®
MD A&U Q2-09 Report, July 13, 2009,
Allergan, Inc.; 3, Data on file. LATISSE®
Consumer A&U Q2-09 Report, July 13, 2009, Allergan, Inc.;
4. Data on file. LATISSE®
Value Proposition, September 2009, Allergan, Inc.
LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Could Be a Catalyst for Medical Aesthetics
Existing patients
5 million existing aesthetic patients place
importance on their lashes1
75% of LATISSE®
users are existing
patients in an MD office (n=273)2
24% of LATISSE®
users are already first-
time buyers of other treatments* from
same MD (n=192)3
New patients
80% are receptive to hearing about
LATISSE®
(n=199)2
25% of MDs report that LATISSE®
has driven new patients into the
practice (n=294)2
MDs report ~23% of LATISSE®
new
patients are cross-sold* (n=203)2
New and existing patients
 Of these patients, 87% of LATISSE®
users already told friends and family (n=189)3
 In an analysis of 576 patients coming in for LATISSE®
, 64% of new and existing
patients received additional products and services (n=576)4
*IIncludes facial injectables and skin care products.
Market Research Shows
Not all consumers are potential LATISSE®
patients. Only a physician can determine
who is an appropriate patient.

29. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Advertising
 Massive consumer campaign to help
drive patient demand:
– Consumer marketing campaigns
developed by Allergan have the potential
to create demand and attract new
patients:
 Advertising and PR: National
exposure across TV, magazines,
and the Internet
 Find a Doctor tool: Links consumers
to Allergan physician customers
 Over 1 billion impressions anticipated
– Brooke, known for her eyes adds instant
brand awareness and recall for LATISSE®
,
which may mean your patients will ask for
LATISSE®
by name!
Please see Important Safety Information on slides 2-6.

30. LATISSE®
(bimatoprost ophthalmic solution) 0.03%:
Practice Analysis Objective and Methodology
Objective
 To support market research findings that patients using LATISSE®
present an opportunity to expand the aesthetic marketplace
Methodology
 39 participating accounts in dispensing and nondispensing states
 Plastic surgeons, dermatologists, and other
 576 LATISSE®
patient consults occurred, which included new and
existing patients
 Consult requests for LATISSE®
only (demand)
 Data on additional products or services purchased during the
consult were captured in the study

31.  Of the 576 patients, 78 patients were in Rx-only states
 97% of patients who came in for LATISSE®
either bought LATISSE®
or received a
prescription for LATISSE®
– 87% purchased LATISSE®
– 13% received a prescription
 64% or 370 patients coming in for LATISSE®
purchased an additional product or
service other than LATISSE®
– 46% facial injectables
– 28% skin care products
– 27% skin care services, including laser
– 4% surgery
LATISSE®
(bimatoprost ophthalmic solution) 0.03%
as a Catalyst: 16-Week Data
576 Patients – 39 Practices
Data on file. LATISSE®
Value Proposition, September 2009, Allergan, Inc.

32. LATISSE®
(bimatoprost ophthalmic solution) 0.03%:
Increasing the Growth of Eyelashes
LATISSE®
is the first and
only treatment approved
by the FDA indicated to
treat hypotrichosis* of the
eyelashes by increasing
their growth including
length, thickness,
and darkness
*Hypotrichosis is another name for having inadequate or not enough eyelashes.
FDA=US Food and Drug Administration.
LATISSE®
[package insert]. Irvine, CA: Allergan, Inc.

33. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Indication: LATISSE®
(bimatoprost ophthalmic solution) 0.03% is
indicated to treat hypotrichosis of the eyelashes by increasing their
growth, including length, thickness, and darkness.
Important Safety Information:
Contraindications: LATISSE®
is contraindicated in patients with
hypersensitivity to bimatoprost or any other ingredient in this product.

34. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Important Safety Information (cont’d)
Warnings and Precautions: In patients using LUMIGAN®
(bimatoprost
ophthalmic solution) 0.03% or other prostaglandin analogs for the
treatment of elevated intraocular pressure (IOP), the concomitant use
of LATISSE®
may interfere with the desired reduction in IOP. Patients
using prostaglandin analogs including LUMIGAN®
for IOP reduction
should only use LATISSE®
after consulting with their physician and
should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when the same formulation of
bimatoprost ophthalmic solution (LUMIGAN®
) was instilled directly onto
the eye. Although iridal pigmentation was not reported in clinical
studies with LATISSE®
, patients should be advised about the potential
for increased brown iris pigmentation which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening)
to periorbital pigmented tissues and eyelashes.

35. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Important Safety Information (cont’d)
Warnings and Precautions (cont’d): There is the potential for hair
growth to occur in areas where LATISSE®
solution comes in repeated
contact with skin surfaces.
LATISSE®
solution should be used with caution in patients with active
intraocular inflammation (eg, uveitis) because the inflammation may be
exacerbated.
LATISSE®
contains benzalkonium chloride, which may be absorbed by
soft contact lenses. Contact lenses should be removed prior to
application of solution and may be reinserted 15 minutes following its
administration.

36. LATISSE®
(bimatoprost ophthalmic solution) 0.03%
Important Safety Information (cont’d)
Adverse Reactions: The most frequently reported adverse events
were eye pruritus, conjunctival hyperemia, skin hyperpigmentation,
ocular irritation, dry eye symptoms, and erythema of the eyelid. These
events occurred in less than 4% of patients.
Dosage and Administration: Apply nightly directly to the skin of the
upper eyelid margin at the base of the eyelashes using the
accompanying applicators. Blot any excess solution beyond the eyelid
margin. Dispose of the applicator after one use. Repeat for the
opposite eyelid margin using a new sterile applicator. Do not apply to
the lower eyelash line.

37. Other Safety Information
Macular edema, including cystoid macular edema, has been reported
during treatment with bimatoprost ophthalmic solution (LUMIGAN®
) for
elevated intraocular pressure (IOP). LATISSE®
should be used with
caution in aphakic patients, in pseudophakic patients with a torn
posterior lens capsule, or in patients with known risk factors for
macular edema.
There have been reports of bacterial keratitis associated with the use
of multiple-dose containers of topical ophthalmic products.
Patients should also be informed of the possibility of disparity between
eyes in length, thickness, pigmentation, number of eyelashes or vellus
hairs, and/or direction of eyelash growth.
For more information on LATISSE®
, please refer to
full prescribing information.
©2010 Allergan, Inc. ® and ™ marks owned by Allergan, Inc.
APC87SE10